The original success of the copyright undeniably reshaped the drug landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. While early earnings were significant, the end of patents and the appearance of cheaper alternatives have eroded market share. Therefore, a thorough evaluation of ongoing income so